Table 3.

HCV Cumulative Deaths, Costs, and QALYs per Person Associated With the United State Age 20+ United States Population^a, and Incremental Results, Assuming CDC Recommended Testing Followed by Treatment With Different Treatment Modalities

Tx by Genotype	Cumulative HCV Deaths	Costs per Person	QALYs per Person	Incremental Deaths	Incremental Costs	Incremental QALYs	ICER
No Treatment	1 181 554	$437	15.656	n/a	n/a	n/a	n/a
	(1 088 653–1 270 476)	($344-$561)	(15.652–15.661)
G1/4 - PR, 48 wks	1 131 638	$517	15.658	−49 916	$80.0	0.0013	$59 792b
G2/3 - PR, 24 wks, 12 Wks	(1 045 343–1 216 951)	($422-$638)	(15.653–15.662)	(−43 311–−53 526)	($76-$78)	(0.0011–0.0015)	(-$205 950–$213 295)
G1/4 - PRPI, 24 wks, 12 Wks	1 106 130	$528	15.658	−75 424	$91	0.0021	$43 530c
G2/3 - PR, 24 wks	(1 022 050–1 190 781)	($433–$648)	(15.654–15.663)	(−66 603–−79 696)	($90–$86)	(0.0018–0.0023)	(-$238 295–$227 433)
G1/4 - PR+ Sofosbuvir, 12 Wks	1 025 448	$642	15.661	−80 682	$114	0.0024	$47 237
G2 - Sofosbuvir + Ribavirin, 12 wks	(945 291–1 106 558)	($542–$758)	(15.657–15.665)	(−76 759–−84 223)	($108–$110)	(0.0021–0.0028)	($34 058–$63 969)
G1/4 – Sofosbuvir + Simeprevir, 12 wks	860 908	$992	15.666	−164 540	$350	0.0048	$72 169
G2 - Sofosbuvir + Ribavirin, 12 wks G3 - Sofosbuvir + Ribavirin, 24 wks	(781 473–936 340)	($835–$1167)	(15.662–15.669)	(−163 818–−170 218)	($294-$410)	(0.0044–0.0053)	($50 931–$102 196)

Abbreviations: CDC, Centers for Disease Control and Prevention; G, genotype; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; PR, pegylated interferon and ribavirin; PRPI, PR + a protease inhibitor such as telaprevir or boceprevir; QALY, quality-adjusted life-year; Tx, Treatment.

^aUnited States Population total used in year 1 of the model = 229 185 985.

^bExtendedly dominated by PRPI.

^cCompared to no treatment.